期刊文献+

顺铂联合培美曲塞或多西他赛治疗晚期非小细胞肺癌的临床疗效及其安全性

Clinical effect and the safety of cisplatin combined with pemetrexed or docetaxel in the treatment of advanced non-small cell lung cancer
下载PDF
导出
摘要 目的探讨顺铂联合培美曲塞或多西他赛治疗晚期非小细胞肺癌(NSCLC)的临床疗效及其安全性。方法选取武警四川省总队医院肿瘤科2015年5月—2016年11月收治的晚期NSCLC患者58例,按照入院顺序分为PP组(n=30)和DP组(n=28)。患者入院后均给予常规基础治疗,PP组患者给予顺铂+培美曲塞治疗方案,DP组患者给予顺铂+多西他赛治疗方案,两组患者均持续治疗2~6个周期。比较两组患者的近期疗效、毒副作用及Karnofsky评分法(KPS)评分。结果两组患者肿瘤控制率比较,差异无统计学意义(P>0.05);PP组患者治疗有效率高于DP组(P<0.05)。两组患者白细胞计数减少、消化道反应发生率及其他毒副作用发生率比较,差异无统计学意义(P>0.05)。治疗前,两组患者KPS评分比较,差异无统计学意义(P>0.05);治疗后,PP组患者KPS评分高于DP组(P<0.05)。结论采用培美曲塞联合顺铂治疗晚期NSCLC的临床疗效优于多西他赛,其可有效提高患者的生活质量,且并不会增加药物毒副作用。 Objective To investigate the clinical effect and the safety of cisplatin combined with pemetrexed or docetaxel in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 58 cases of patients with advanced NSCLC were selected from May 2015 to November 2016 in Department of Oncology of Sichuan General Hospital of Armed Police Forces,which were divided into PP group(n=30) and DP group(n=28) according to hospital order.All groups were given basic treatments,PP group was treated with cisplatin+pemetrexed,and DP group was treated with cisplatin+docetaxel,both groups were treated for 2-6 cycles.The clinical effect,toxic and side effects and KPS scores before and after treatment were compared between the two groups.Results There was no statistically significant difference of tumor control rate between the two groups(P〈0.05);PP group of treatment effective rate was higher than DP group(P〈0.05).No statistically significant differences of the rate of reduction of white blood cell count,gastrointestinal reaction or others was found between the two groups(P〈0.05).Before treatment,no statistically significant difference of KPS scores was found between the two groups(P〈0.05);after treatment,the PP group of KPS scores was higher than DP group(P〈0.05).Conclusion Pemetrexed combined with cisplatin has an exactly clinical effect in the treatment of advanced NSCLC,it can significantly improve the quality of life,and will not increase the toxic and side effects of drugs.
出处 《临床合理用药杂志》 2017年第18期7-8,10,共3页 Chinese Journal of Clinical Rational Drug Use
关键词 非小细胞肺 顺铂 培美曲塞 多西他赛 治疗结果 Carcinoma non-small-cell lung Cisplatin Pemetrexed Docetaxel Treatment outcome
  • 相关文献

参考文献8

二级参考文献103

  • 1李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量:73
  • 2Ohe Y. Chemoradiotherapy for lung cancer[ J]. Expert Opin Phar- macother, 2005,6(16) :2793-2804.
  • 3Fossella F, Pereira JR, van Pawel J, et al. Randomized, multina- tional, phase I study of docetaxel plus platinum combinations ver- sus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group [ J]. J Clin Oncol, 2003,21 (16) :3016-3024.
  • 4Scagliotti GV, Parikh P, yon Pawel J, et al. Phase m study com- paring cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive pa tients with advanced-stage non-small-cell lung cancer[J]: J Clin Oncol, 2008,26(21 ) :3543-3551.
  • 5Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized,phase 1/ trial[J]. Clin Cancer Res, 2005,11(2 Pt 1) : 690-696.
  • 6Zinner RG, Fossella FV, Gladish GW, et al. Phase 11 study of pemetrexed in combination with carboplatin in the first-line treal- ment of advanced nonsmall cell lung cancer [ J ]. Cancer, 2005, 104( 11 ) :2449-2456.
  • 7Scagliotti GV, Park K, Patil S, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in che- monaive patients with advanced non-small cell lung cancer: a risk- benefit analysis of a large phase I study [ J ]. Eur J Cancer, 2009,45 ( 13 ) :2298-2303.
  • 8Greenhalgh J, McLeod C, Bagust A, et al. Pemetrexed for the ma- intenance treatment of locally advanced or metastatic non-small cell lung cancer[ J ]. Health Technol Assess, 2010,14 ( Suppl 2) : 33- 39.
  • 9Hainsworth JD, Cebotam CL, Kanarev V, et al. A phase l/ , open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small-cell lung cancer who have failed one or two prior chemo- therapeutic regimens [ J ]. J Thorac Oncol, 2010,5 ( 10 ) : 1630- 1636.
  • 10Felip E, Rosell R. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC) [ J]. Ther Clin Risk Manag, 2008_ 4 ( 3 ) .579-5.

共引文献129

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部